Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | RAD51D |
Variant | V200* |
Impact List | nonsense |
Protein Effect | loss of function |
Gene Variant Descriptions | RAD51D V200* results in a premature truncation of the Rad51d protein at amino acid 200 of 328 (UniProt.org). V200* results in decreased Rad51d protein stability, impaired DNA homologous recombination activity and DNA damage response, and increased sensitivity to PARP inhibitors in culture (PMID: 33151324). |
Associated Drug Resistance | |
Category Variants Paths |
RAD51D mutant RAD51D inact mut RAD51D V200* |
Transcript | NM_002878.4 |
gDNA | chr17:g.35103522_35103523delGTinsTA |
cDNA | c.598_599delGTinsTA |
Protein | p.V200* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002878.3 | chr17:g.35103522_35103523delGTinsTA | c.598_599delGTinsTA | p.V200* | RefSeq | GRCh38/hg38 |
NM_002878.4 | chr17:g.35103522_35103523delGTinsTA | c.598_599delGTinsTA | p.V200* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RAD51D V200* | triple-receptor negative breast cancer | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment inhibited viability of triple-negative breast cancer cells expressing RAD51D V200* in culture (PMID: 33151324). | 33151324 |